Epidemiology and natural history of human papillomavirus infections in the female genital tract

Infectious Diseases in Obstetrics and Gynecology

Volumn 2006, Issue , 2006, Pages

  Ault, Kevin A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; PAPILLOMA VIRUS VACCINE;

ARTICLE; CELL DAMAGE; CHLAMYDIA TRACHOMATIS; CLINICAL FEATURE; CONDYLOMA; FEMALE GENITAL SYSTEM; HEALTH CARE COST; HERPES SIMPLEX; HIGH RISK PATIENT; HUMAN; IMMUNE SYSTEM; MORBIDITY; MORTALITY; PAPANICOLAOU TEST; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; SQUAMOUS EPITHELIUM; UNITED STATES; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS TRANSMISSION; WART VIRUS; ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; CHILD; CONDYLOMA ACUMINATUM; FEMALE; INCIDENCE; MALE; MIDDLE AGED; PATHOGENICITY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; UTERINE CERVIX TUMOR; VIROLOGY;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; CHILD; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES, VIRAL; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 33645220403     PISSN: 10647449     EISSN: 10980997     Source Type: Journal    
DOI: 10.1155/IDOG/2006/40470     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention. Genital HPV Infection - CDC Fact Sheet. Centers for Disease Control and Prevention. 2004.
2. Koutsky LA. Epidemiology of genital human papillomavirus infection. The American Journal of Medicine. 1997;102(5 suppl 1):3-8.
3. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. American Journal of Epidemiology. 2003;157(3):218-226.
4. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. The Journal of Infectious Diseases. 2005;191(2):182-192.
5. Marrazzo JM, Koutsky LA, Kiviat NB, Kuypers JM, Stine K. Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. American Journal of Public Health. 2001;91(6):947-952.
6. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. The Journal of Infectious Diseases. 2002;186(10):1396-1402.
7. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sexually Transmitted Diseases. 2002;29(11):725-735.
8. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. International Journal of Cancer. 2003;107(5):811-816.
9. Scheurer ME, Tortolero-Luna G, Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. International Journal of Gynecological Cancer. 2005;15(5):727-746.
10. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiology and Molecular Biology Reviews. 2004;68(2):362-372.
11. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. Journal of the National Cancer Institute. 2000;92(9):690-698.
12. Mao C, Hughes JP, Kiviat NB, et al. Clinical findings among young women with genital human papillomavirus infection. American Journal of Obstetrics and Gynecology. 2003;188(3):677-684.
13. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. Journal of the National Cancer Institute. 2003;95(1):46-52.
14. Castellsagué X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis - role of parity, oral contraceptives, and tobacco smoking. Journal of the National Cancer Institute Monographs. 2003;(31):20-28.
15. Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. Journal of the National Cancer Institute. 2002;94(21):1604-1613.
16. Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA: The Journal of the American Medical Association. 2001;285(1):47-51.
17. Samoff E, Koumans EH, Markowitz LE, et al. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. American Journal of Epidemiology. 2005;162(7):668-675.
18. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. Journal of the National Cancer Institute. 2005;97(8):577-586.
19. Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA: The Journal of the American Medical Association. 2005;293(12):1471-1476.
20. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. The Journal of Infectious Diseases. 2005;191(5):731-738.
21. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. Journal of the National Cancer Institute. 2005;97(14):1072-1079.
22. Cox JT. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors. Archives of Pathology & Laboratory Medicine. 2003;127(8):950-958.
23. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. American Journal of Obstetrics and Gynecology. 2004;191(1):114-120.
24. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clinical Infectious Diseases. 2003;36(11):1397-1403.
25. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. The Lancet. 2004;364(9447):1757-1765.
26. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase 3 efficacy trial. The Lancet Oncology. 2005;6(5):271-278.
27. Skjeldestad FE. FUTURE II steering committee. Prophylactic Quadrivalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine (Gardasil) Reduces Cervical Intraepithelial Neoplasia (CIN) 2/3 Risk. In: 43rd Annual Meeting of IDSA; October 2005; San Francisco, Calif.